welcome to DuchenneXchange
- a positively charged Duchenne muscular dystrophy community.- join today!
- login
Capricor to Meet with FDA under its RMAT Designation to Discuss HOPE-2 Clinical Trial
Capricor Therapeutics announced today that it will meet with the U.S. Food and Drug Administration (FDA) in December to discuss clinical trial design, surrogate or intermediate endpoints and manufacturing processes for CAP-1002, Capricor’s novel cell therapy. Currently, patients are being enrolled in the HOPE-2 clinical trial, which is investigating CAP-1002 as a therapy for the treatment of Duchenne muscular dystrophy.
The in-person meeting is part of the expedited review process afforded to Capricor for its CAP-1002 product candidate after being granted the Regenerative Medicine Advanced Therapy (RMAT) designation by the FDA in February 2018. The FDA grants the RMAT designation to regenerative medicine therapies intended to treat a serious condition and for which preliminary clinical evidence indicates a potential to address unmet medical needs for that condition.
rareRelated
-
European Home Mechanical Ventilation RegistryThe European Home Mechanical Ventilation...
-
Pathway Key to Muscle Regeneration Doesn’t Work as It Should in Duchenne, Study FindsThe Hippo signaling pathway — a key re...
-
Plus Epicatechin Duchenne Muscular Dystrophy in Non-ambulatory AdolescentsThis single center open-label pilot stud...
-
Bone Marrow-Derived Autologous Stem Cells for the Treatment of Duchenne Muscular DystrophyThis study is single arm, single center ...
-
A Study of CAP-1002 in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy (HOPE-2)HOPE-2 is a double-blind clinical trial ...
-
Nearly Half of Duchenne Muscular Dystrophy Patients Are Candidates for Gene TherapiesMore than 40 percent of boys with Duchen...
-
Phase IIa trial in Duchenne muscular dystrophy shows vamorolone is a first-in-class dissociative steroidal anti-infl...We report a first-in-patient study of va...
-
Santhera to Present Long-term Efficacy Results with Idebenone in DMD at the 2019 MDA Clinical and Scientific Confere...Santhera Pharmaceuticals and its collabo...
-
Duchenne Muscular Dystrophy Awaits Gene TherapySolid’s gene therapy disappoints in th...
